A Multicenter, Open-label, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous And/or Intravenous Pf-06741086 In Subjects With Severe Hemophilia
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs PF 6741086 (Primary) ; PF 6741086 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 18 May 2017 Planned End Date changed from 25 Nov 2018 to 30 Nov 2018.
- 18 May 2017 Planned primary completion date changed from 25 Nov 2018 to 30 Nov 2018.